Vancomycin: the need to suit serum concentrations in hemodialysis patients

被引：0

作者：

Marengo, Livia Luize ^{[1
]}

Del Fiol, Fernando de Sa ^{[2
]}

Oliveira, Sara de Jesus ^{[2
]}

Nakagawa, Celso ^{[3
]}

Croco, Eduardo Leite ^{[3
]}

Barberato-Filho, Silvio ^{[2
]}

Pecanha, Marcela Pellegrini ^{[4
]}

da Silva, Douglas Felix ^{[2
]}

de Toledo, Maria Ines ^{[2
,5
]}

机构：

[1] Univ Sorocaba PIBIC CNPq, Sch Pharm, Campinas, SP, Brazil

[2] Univ Sorocaba, CRIA, Sorocaba, Brazil

[3] Conjunto Hosp Sorocaba, Sorocaba, Brazil

[4] PUC Sao Paulo, Fac Ciencias Med Saude, Sao Paulo, Brazil

[5] Fac Tecnol Sorocaba, Sorocaba, Brazil

来源：

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES | 2010年 / 14卷 / 02期

关键词：

vancomycin; chronic renal failure; hemodialysis; RESISTANT STAPHYLOCOCCUS-AUREUS; PHARMACOKINETICS; BACTEREMIA;

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The vancomycin dose for hemodialysis (HD) patients should be adjusted by monitoring drug serum concentrations. However, this procedure is not available in most health services in Brazil, which usually adopts protocols based on published studies. The trials available are controversial, and several have not been conducted with current dialyzers. This study aimed at assessing the suitability of vancomycin serum concentrations in HD patients at a public hospital. Blood samples of HD patients were collected from November 2006 to May 2007, at time intervals of 48, 96, 120, or 168 hours after vancomycin administration. Drug measurement was performed with polarized light immunofluorescence. Approximately 86% of trough vancomycin serum concentrations were below the recommended value, indicating exposure to subtherapeutic doses and a higher risk for selecting resistant microorganisms.

引用

页码：203 / 208

页数：6

共 27 条

[1] BARTLETT JG, 2004, ANTIBIOTIC SELECTION
[2] Bernardes RC, 2004, REV BIOCIENCIAS, V10, P73
[3] Optimal vancomycin serum level in Staphylococcus aureus infections
Bingen, E.
Mariani-Kurkdjian, P.
Nebbad, B.
[J]. MEDECINE ET MALADIES INFECTIEUSES, 2006, 36 (09): : 439 - 442
[4] Safety and efficacy of glycopeptide antibiotics
Finch, RG
Eliopoulos, GM
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 : 5 - 13
[5] Foote EF, 1998, CLIN NEPHROL, V50, P51
[6] Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala
Ge, M
Chen, Z
Onishi, HR
Kohler, J
Silver, LL
Kerns, R
Fukuzawa, S
Thompson, C
Kahne, D
[J]. SCIENCE, 1999, 284 (5413) : 507 - 511
[7] GOLDMAN L, 2005, CECIL TRATADO MED IN, V22
[8] GonzalezMartin G, 1996, INT J CLIN PHARM TH, V34, P71
[9] Glycopeptide-resistant Staphylococcus aureus
Johnson, AP
Woodford, N
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) : 621 - 623
[10] Klasco RK, 1974, MARTINDALE EXTRA PHA

← 1 2 3 →